Table 1.

Multivariate analysis for TTP in patients receiving trastuzumab-based chemotherapy

VariableHR (95% CI)P
β1-Integrin score 3+2.6 (1.47–4.10)0.0089
Tumor size >2 cm1.63 (0.94–2.81)0.011
Lymph node–positive1.48 (0.83–2.6)0.18
ER-positive0.79 (0.49–1.27)0.34
PR-positive0.93 (0.52–1.24)0.83
LVI-positive0.7 (0.41–1.17)0.17
Trastuzumab-based chemotherapy0.89 (0.31–1.17)0.13

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; LVI, lymphovascular invasion.